Patient characteristics
| Characteristics . | Patients (N = 28) (%) . |
|---|---|
| Sex, n (%) | |
| Male | 18 (64) |
| Female | 10 (36) |
| Ethnicity | |
| Caucasian | 28 (100) |
| Age (y) | |
| Median | 65 (IQR, 57-69 y) |
| Range | 46-72 |
| ECOG performance status score (%) | |
| 0-1 | 22 |
| >1 | 6 |
| Ann Arbor stage III or IV, n (%) | 28 (100) |
| Bone marrow involvement | |
| Yes | 26 |
| No | 2 |
| MIPI score, n (%) category | TB |
| Low | 0 (0) |
| Intermediate | 10 (6) |
| High | 18 (88) |
| Variant, n (%) | |
| Blastoid/blastic | 4 (14) |
| Pleomorphic | 2 (7) |
| Ki-67 | |
| <30% | 8 (1 not reported at City of Hope) |
| 30% | 19 |
| p53 status | |
| Deleted | 2 (1 had concurrent mutation) |
| Mutated | 5∗ |
| Cytogenetics at diagnosis | |
| 19 | Normal |
| 8 | Abnormal |
| 1 | Unknown |
| Unfit or ineligible for high-dose chemotherapy | 3 patients 2 patients for age/fitness 1 patient concurrent medical condition |
| Characteristics . | Patients (N = 28) (%) . |
|---|---|
| Sex, n (%) | |
| Male | 18 (64) |
| Female | 10 (36) |
| Ethnicity | |
| Caucasian | 28 (100) |
| Age (y) | |
| Median | 65 (IQR, 57-69 y) |
| Range | 46-72 |
| ECOG performance status score (%) | |
| 0-1 | 22 |
| >1 | 6 |
| Ann Arbor stage III or IV, n (%) | 28 (100) |
| Bone marrow involvement | |
| Yes | 26 |
| No | 2 |
| MIPI score, n (%) category | TB |
| Low | 0 (0) |
| Intermediate | 10 (6) |
| High | 18 (88) |
| Variant, n (%) | |
| Blastoid/blastic | 4 (14) |
| Pleomorphic | 2 (7) |
| Ki-67 | |
| <30% | 8 (1 not reported at City of Hope) |
| 30% | 19 |
| p53 status | |
| Deleted | 2 (1 had concurrent mutation) |
| Mutated | 5∗ |
| Cytogenetics at diagnosis | |
| 19 | Normal |
| 8 | Abnormal |
| 1 | Unknown |
| Unfit or ineligible for high-dose chemotherapy | 3 patients 2 patients for age/fitness 1 patient concurrent medical condition |
COH; IQR, interquartile range; MIPI, Mantle Cell Lymphoma International Prognostic Index.